Win Farma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 6 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 1.00 M
About Win Farma
Win Farma Private Limited (WFPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 August 2014 and has a history of Ten years and six months. Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Sibbala Sujatha and Sibbala Karunakar serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51909TN2014PTC096757
- Company No.
096757
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Aug 2014
- Date of AGM
05 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
What products or services does Win Farma Private Limited offer?
Win Farma Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Aceclofenac Tablet, Aceclofenac Paracetamol Serratiopeptidase Tablet.
Who are the key members and board of directors at Win Farma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sibbala Sujatha  | Director | 01-Aug-2014 | Current |
| Sibbala Karunakar | Director | 01-Aug-2014 | Current |
Financial Performance of Win Farma.
Enhance accessibility to Win Farma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Win Farma?
Unlock access to Win Farma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of India : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Oct 2016 | Bank Of India | ₹1.00 M | Open |
How Many Employees Work at Win Farma?
Unlock and access historical data on people associated with Win Farma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Win Farma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Win Farma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.